Form 8-K Moderna, Inc. For: May 02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
Moderna (MRNA) PT Raised to $135 at RBC Capital
May 3, 2024 6:45 AM EDTRBC Capital analyst Luca Issi raised the price target on Moderna (NASDAQ: MRNA) to $135.00 (from $125.00) while maintaining a Outperform rating.
The analyst comments "Bottom line was a beat primarily on lower OpEx. Guide was reiterated ($4b revenue and $8.1b costs), and we like... More
Moderna (MRNA) PT Raised to $95 at Morgan Stanley
May 2, 2024 4:14 PM EDTMorgan Stanley analyst Matthew Harrison raised the price target on Moderna (NASDAQ: MRNA) to $95.00 (from $89.00) while maintaining a Equalweight rating.
The analyst comments "Generally in line quarter, looking ahead the next catalysts for the stock are RSV vaccine PDUFA date May 12 (followed... More
